Gilead Sciences/$GILD
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Gilead Sciences
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
Ticker
$GILD
Sector
Primary listing
Employees
17,600
Headquarters
Website
Gilead Sciences Metrics
BasicAdvanced
$150B
18.87
$6.42
0.33
$3.14
2.61%
Price and volume
Market cap
$150B
Beta
0.33
52-week high
$128.70
52-week low
$88.57
Average daily volume
7.1M
Dividend rate
$3.14
Financial strength
Current ratio
1.453
Quick ratio
1.105
Long term debt to equity
103.165
Total debt to equity
115.492
Dividend payout ratio (TTM)
48.31%
Interest coverage (TTM)
11.17%
Profitability
EBITDA (TTM)
14,136
Gross margin (TTM)
78.72%
Net profit margin (TTM)
27.88%
Operating margin (TTM)
39.09%
Effective tax rate (TTM)
17.96%
Revenue per employee (TTM)
$1,650,000
Management effectiveness
Return on assets (TTM)
12.38%
Return on equity (TTM)
40.71%
Valuation
Price to earnings (TTM)
18.869
Price to revenue (TTM)
5.189
Price to book
7.02
Price to tangible book (TTM)
-31.73
Price to free cash flow (TTM)
16.475
Free cash flow yield (TTM)
6.07%
Free cash flow per share (TTM)
7.356
Dividend yield (TTM)
2.59%
Forward dividend yield
2.61%
Growth
Revenue change (TTM)
2.78%
Earnings per share change (TTM)
6,514.05%
3-year revenue growth (CAGR)
2.34%
10-year revenue growth (CAGR)
-0.78%
3-year earnings per share growth (CAGR)
34.50%
10-year earnings per share growth (CAGR)
-5.14%
3-year dividend per share growth (CAGR)
2.69%
10-year dividend per share growth (CAGR)
13.83%
What the Analysts think about Gilead Sciences
Analyst ratings (Buy, Hold, Sell) for Gilead Sciences stock.
Gilead Sciences Financial Performance
Revenues and expenses
Gilead Sciences Earnings Performance
Company profitability
Gilead Sciences News
AllArticlesVideos
Yescarta® Delivers Consistent Safety, Efficacy, and Quality of Life Benefits Across Broad Range of Relapsed/Refractory Large B-cell Lymphoma Patients in New Analysis at ASH 2025
Business Wire·3 days ago
Kite Announces New Data for Pivotal iMMagine-1 Study at ASH 2025, Highlighting Anito-cel's Opportunity in Relapsed or Refractory Multiple Myeloma
Business Wire·3 days ago
Kite's Next-Generation Bicistronic CAR T-Cell Therapies Show Encouraging Phase 1 Results in Relapsed/Refractory B-Cell Lymphoma in New Data at ASH 2025
Business Wire·3 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
FAQs
What’s the current market cap for Gilead Sciences stock?
Gilead Sciences (GILD) has a market cap of $150B as of December 10, 2025.
What is the P/E ratio for Gilead Sciences stock?
The price to earnings (P/E) ratio for Gilead Sciences (GILD) stock is 18.87 as of December 10, 2025.
Does Gilead Sciences stock pay dividends?
Yes, the Gilead Sciences (GILD) stock pays dividends to shareholders. As of December 10, 2025, the dividend rate is $3.14 and the yield is 2.61%. Gilead Sciences has a payout ratio of 48.31% on a trailing twelve-month basis.
When is the next Gilead Sciences dividend payment date?
The next Gilead Sciences (GILD) dividend payment is scheduled for December 30, 2025.
What is the beta indicator for Gilead Sciences?
Gilead Sciences (GILD) has a beta rating of 0.33. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.